We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current LXRX market cap is 445.76M. The company's latest EPS is USD -0.7232 and P/E is -2.48.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 39k | 28k | 24k | 316k | 162k |
| Operating Income | -23.1M | -30.28M | -31.14M | -44.24M | -49.63M |
| Net Income | -23.39M | -30.49M | -31.93M | -44.9M | -50.53M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 322.07M | 24M | 298k | 139k | 1.2M |
| Operating Income | 141.45M | -180.39M | -87.09M | -100.76M | -171.75M |
| Net Income | 130.13M | -58.57M | -87.76M | -101.94M | -177.12M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 191.69M | 194.3M | 162.72M | 316.72M | 276.48M |
| Total Liabilities | 47.67M | 77.18M | 74.67M | 130.36M | 136.97M |
| Total Equity | 144.02M | 117.12M | 88.05M | 186.36M | 139.51M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 417.72M | 203.79M | 136.91M | 194.3M | 229.43M |
| Total Liabilities | 300.61M | 47.42M | 23.31M | 77.18M | 136.32M |
| Total Equity | 117.1M | 156.37M | 113.6M | 117.12M | 93.11M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -67.28M | -88.85M | -31.61M | -69.73M | -111.35M |
| Investing | -95.25M | -71.08M | 12.09M | -62.52M | -101.84M |
| Financing | 117.3M | 142.21M | -824k | 188.17M | 187.96M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 113.81M | -142.97M | -87.02M | -88.85M | -161.9M |
| Investing | -155.86M | 380.76M | 2.11M | -71.08M | -49.94M |
| Financing | -2.23M | -147.64M | 22.71M | 142.21M | 187.96M |
| Market Cap | 445.76M |
| Price to Earnings Ratio | -2.48 |
| Price to Sales Ratio | 365.31 |
| Price to Cash Ratio | 19.52 |
| Price to Book Ratio | 4.71 |
| Dividend Yield | - |
| Shares Outstanding | 244.92M |
| Average Volume (1 week) | 3.75M |
| Average Volume (1 Month) | 3.02M |
| 52 Week Change | -26.91% |
| 52 Week High | 3.789 |
| 52 Week Low | 0.92 |
| Spread (Intraday) | 0.01 (0.55%) |
| Company Name | Lexicon Pharmaceuticals Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.lexpharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
